800 BRIDGE PARKWAY, REDWOOD CITY, CA
Completion of Acquisition - Arcellx, Inc. Merges with Gilead Sciences
Material Contracts, Reg. FD
Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Provides Third Quarter 2025 Financial Results
Provides Second Quarter 2025 Financial Results and Business Highlights
Shareholder votes
Provides First Quarter 2025 Financial Results and Business Highlights
Amended Annual Report
FY 2024
Q3
Q2
Q1
FY 2023
Notice of Suspension of Duty to File Reports
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Amended Schedule 14D-9 Solicitation/Recommendation Statement
Amended Tender Offer Statement by Third Party